{"disease":{"id":"cin3","name":"cin3"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04422366","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05584332","title":"A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3131,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT04425291","title":"Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1680,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05027776","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1348,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05372016","title":"Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Shanghai Bovax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06147388","title":"Regression of Cervical Precancerous Lesions and Associated Risk Factors","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"General University Hospital, Prague","has_results":false},{"nct_id":"NCT05413811","title":"Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06015854","title":"Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"University Medical Center Groningen","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}